Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya MM, Whittaker M, Minassian AM, O'Hara GA, Hamill M, Scott JT, Harris SA, Poyntz HC, Bateman C, Meyer J, Williams N, Gilbert SC, Lawrie AM, Hill AV, McShane H.

Hum Vaccin Immunother. 2013 Jan;9(1):50-62. doi: 10.4161/hv.22464. Epub 2012 Nov 10.

PMID:
23143773
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults.

Nicol MP, Grobler LA.

Curr Opin Mol Ther. 2010 Feb;12(1):124-34. Review.

PMID:
20140824
[PubMed - indexed for MEDLINE]
3.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
[PubMed - indexed for MEDLINE]
4.

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.

McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52. Epub 2005 Jan 21. Review.

PMID:
15687027
[PubMed - indexed for MEDLINE]
5.

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV.

Vaccine. 2006 May 22;24(21):4554-61. Epub 2005 Aug 24. Review.

PMID:
16150517
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk